Streetbeat News

Revenues

SMRT

SmartRent forecasts its Q1 total revenue to be between $47M-$53M, falling short of the estimated $64.92M. For 2024, the company projects revenues of $260M-$290M, slightly below the estimated $289.256M.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:06 pm

CASY

Casey's General Stores (NASDAQ:CASY) has received mixed analyst ratings over the past three months, with an average 12-month price target of $315.6, indicating a 5.08% increase from the previous target. Analysts from Wells Fargo, Benchmark, Stephens & Co., RBC Capital, and BMO Capital have provided updates, with most raising their price targets. The company's financial performance shows positive revenue growth, a strong net margin, and effective debt management, positioning it well in the market.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 1:02 pm

ANSS

Analyst ratings for Ansys (NASDAQ:ANSS) have shown a mix of neutrality and slight bearishness over the last quarter, with a recent shift towards a more neutral stance in the last 30 days. The average 12-month price target for ANSS has been raised to $340.0, indicating a 2.41% increase from the previous target. Ansys's financial performance showcases strong revenue growth and net margin, but a below-average Return on Equity (ROE).

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 1:02 pm

GFS

GLOBALFOUNDRIES (NASDAQ:GFS) received mixed analyst ratings over the past three months, with a shift towards a more cautious stance in the last 30 days. The average 12-month price target is $63.43, down 5.33% from the previous target. The company, a top-five contract semiconductor manufacturer, has shown a revenue growth rate of 0.11% as of December 31, 2023, but faces challenges in market capitalization, net margin, ROE, and ROA compared to industry benchmarks. Its debt-to-equity ratio is below the industry average, indicating less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 1:01 pm

DSP

Viant Technology (NASDAQ:DSP) received mixed analyst ratings, with a recent shift towards more positive evaluations. The average 12-month price target is $10.5, reflecting a 29.31% increase from the previous target. The company's financial performance shows strong revenue growth and profitability metrics, outperforming industry averages. Analysts from Canaccord Genuity, Needham, and Raymond James have raised their price targets and ratings, indicating a positive outlook on the company's future.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 1:00 pm

GWW

Seven financial analysts have recently updated their ratings on W.W. Grainger (NYSE:GWW), showing a shift towards a more positive outlook with an average 12-month price target of $958.86, up from $864.00. The updates include raised price targets from analysts at Oppenheimer, Loop Capital, JP Morgan, Stephens & Co., RBC Capital, and Jefferies, reflecting changes in market conditions and company performance. W.W. Grainger, a major distributor of maintenance and repair products, has shown solid revenue growth and strong financial health, despite a net margin below industry averages.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 1:00 pm

GBTG

American Express Global Business Travel, a part of Global Business Travel Group (GBTG), forecasts its FY24 revenue to be between $2.43B and $2.50B, which is slightly below the estimated $2.51B.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:51 pm

GBTG

Global Business Travel (NYSE:GBTG) reported Q4 sales of $549.00M, surpassing the analyst consensus estimate of $541.17M by 1.45% and marking a 4.17% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:49 pm

STIM

Neuronetics projects Q1 FY 2024 sales to be between $16.7M-$17.7M and full-year sales to reach $78M-$80M, aligning closely with consensus estimates of $16.98M for Q1 and $78.64M for the year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:33 pm

ABBV

Dragonfly Therapeutics has received a milestone payment after the first patient was dosed in a clinical trial by AbbVie. The trial is evaluating ABBV-303, a treatment targeting solid tumors. This development marks a significant step in the collaboration between Dragonfly Therapeutics and AbbVie, potentially impacting the progress and valuation of ABBV-303.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:17 pm